lapaʻau ʻaʻole liʻiliʻi maʻi kanesa

ʻO ka mālama ʻana i ka maʻi maʻi maʻi ʻaʻai liʻiliʻi liʻiliʻi (NSCLC) ʻokoʻa nā koho a hilinaʻi i ke kahua, subtype, a me nā mea maʻi pilikino. ʻO nā lāʻau lapaʻau maʻamau, ʻo ia ka ʻokiʻoki, radiation therapy, chemotherapy, targeted therapy, a me immunotherapy, hoʻohana pinepine ʻia i ka hui pū ʻana. E ʻimi ana kēia alakaʻi i kēlā me kēia koho i nā kikoʻī, e kōkua ana iā ʻoe e hoʻomaopopo i nā mea hiki a hana i nā hoʻoholo hoʻoholo ma ke kūkākūkā ʻana me kāu hui mālama ola. Understanding Non-Small Cell Lung Cancer (NSCLC)He aha ka NSCLC?ʻO ka maʻi maʻi ʻaʻai māmā liʻiliʻi ʻole (NSCLC) ʻo ia ke ʻano maʻamau o ka maʻi maʻi ʻaʻai māmā, ʻo ia hoʻi ma kahi o 80-85% o nā hihia maʻi maʻi maʻi āpau. He hua'ōlelo umbrella ia e pili ana i kekahi mau ʻano subtypes, ʻo ka mea maʻamau ʻo ia ka adenocarcinoma, squamous cell carcinoma, a me ka maʻi maʻi maʻi nui. Hoʻoholo ʻia ka pae e ka nui a me kahi o ka ʻōpū, inā ua laha ʻia i nā ʻōpū lymph kokoke, a inā paha ua metastasized i nā ʻōpū mamao. ʻO nā koho lapaʻau no ka NSCLCSurgery ʻO ke kaʻina hana ka mea maʻamau ka mālama mua ʻana no ka NSCLC mua. ʻO ka pahuhopu, ʻo ia ka wehe ʻana i ke koko a me nā pūnaʻi lymph kokoke i loaʻa i nā maʻi kanesa. Lobectomy: Ka wehe ʻana i kahi lobe holoʻokoʻa o ka māmā. Pneumonectomy: Ka wehe ʻana i kahi māmā holoʻokoʻa. Wedge Resection: Ka wehe ʻana i kahi ʻāpana liʻiliʻi o ke akemāmā. Hoʻokaʻawale ʻia: ʻO ka wehe ʻana i kahi ʻāpana o ka māmā, ʻoi aku ka nui ma mua o ka ʻoki ʻoki ʻana akā ʻoi aku ka liʻiliʻi ma mua o ka lobectomy.Nānā: ʻAʻole paha he koho no ka poʻe maʻi me ka NSCLC kiʻekiʻe a i ʻole ka poʻe me nā maʻi olakino ʻē aʻe i pilikia loa ke kaʻina hana. Hiki ke hoʻohana ʻia e mālama i ka NSCLC ma nā ʻano he nui: ʻO ka hoʻomaʻamaʻa ʻana i ka lāʻau lapaʻau waho (EBRT): Hāʻawi ʻia ka radiation mai kahi mīkini ma waho o ke kino. ʻO ka hoʻomaʻamaʻa ʻana o ke kino stereootactic (SBRT): He ʻano kikoʻī loa o EBRT e hāʻawi ana i ka nui o ka radiation i kahi wahi liʻiliʻi. Hoʻohana pinepine ʻia no ka maʻi maʻi maʻi maʻi maʻi mua ke hiki ʻole ke ʻoki. Brachytherapy: Hoʻokomo pololei ʻia nā mea radioactive i loko a kokoke paha i ka tumor. Hiki ke hoʻohana ʻia ka lāʻau lapaʻau hoʻokahi a i hui pū ʻia me nā lāʻau lapaʻau ʻē aʻe, e like me ka chemotherapy. Mākou ma Shandong Baofa Cancer Research Institute e hoʻomaopopo i ke koʻikoʻi o ka hoʻohui ʻana i nā lāʻau lapaʻau no nā hopena maikaʻi loa. He alakaʻi ʻo Baofa i ka mālama ʻana i ka maʻi kanesa. Hoʻohana pinepine ʻia e mālama i ka NSCLC kiʻekiʻe a i ʻole e pale i ka maʻi maʻi mai ka hoʻi hou ʻana ma hope o ka ʻoki ʻana. ʻO nā lāʻau lapaʻau lapaʻau maʻamau no ka NSCLC: Cisplatin Carboplatin Pemetrexed Docetaxel Paclitaxel Hāʻawi ʻia ke kemotherapy i nā pōʻai, me nā manawa lapaʻau a ukali ʻia e nā manawa hoʻomaha. Hiki ke ʻokoʻa nā hopena ʻaoʻao ma muli o nā lāʻau i hoʻohana ʻia a me ka mea maʻi. ʻOi aku ka maikaʻi o kēia mau lāʻau lapaʻau a ʻoi aku ka liʻiliʻi o nā hopena ʻaoʻao ma mua o ka chemotherapy. ʻO nā lāʻau lapaʻau i hoʻopaʻa ʻia no ka poʻe maʻi me nā hoʻololi genetic kikoʻī. Loaʻa nā pahuhopu maʻamau: EGFR: Epidermal Growth Factor Receptor ALK: Anaplastic Lymphoma Kinase ROS1: ROS1 Proto-Oncogene Receptor Tyrosine Kinase BRAF: B-Raf Proto-Oncogene, Serine/Threonine Kinase NTRK: Neurotrophic Tyrosine Receptor Kinase ʻO nā hiʻohiʻona o nā lāʻau lapaʻau i hoʻopaʻa ʻia i hoʻohana ʻia no NSCLC e like me: Gefitinib (Iressa) Erlotinib (Tarceva) Afatinib (Gilotrif) Osimertinib (Tagrisso) Crizotinib (Xalkori) Ceritinib (Zykadia) Alectinib (Alecensa) Alectinib (Alecensa) hoʻohana ʻia ka hoʻololi ʻana.ImmunotherapyImmunotherapy hoʻohana i nā lāʻau lapaʻau e kōkua i ke kino o ke kino e hakakā i ka maʻi kanesa. Hiki i kēia mau lāʻau ke hoʻopaʻa i nā protein e pale ai i ka ʻōnaehana pale mai ka hoʻouka ʻana i nā maʻi maʻi maʻi. ʻO nā lāʻau lapaʻau immunotherapy maʻamau no ka NSCLC penei: Pembrolizumab (Keytruda) Nivolumab (Opdivo) Atezolizumab (Tecentriq) Durvalumab (Imfinzi) Hiki ke hoʻohana wale ʻia ka immunotherapy a i hui pū ʻia me ka chemotherapy a i ʻole nā ​​lāʻau lapaʻau ʻē aʻe. Hiki i nā hopena ʻaoʻao ke komo i ka luhi, ka ʻili ʻili, a me ka mumū o nā ʻano ʻano like ʻole. NSCLC Treatment by StageStage I NSCLCSurgery is often the first treatment for Stage I NSCLC. Hiki ke noʻonoʻo ʻia ka SBRT inā ʻaʻole ka mea maʻi he moho ʻoki. Hiki ke hoʻohana ʻia ka lāʻau lapaʻau. Hiki ke hoʻohana ʻia ka Immunotherapy ma hope o ka chemoradiation i kekahi mau hihia.Stage IV NSCLCTtreatment for Stage IV NSCLC focused on controling the growth of the cancer and relieving symptoms. Hiki i nā koho ke komo i ka chemotherapy, ka lāʻau lapaʻau i manaʻo ʻia, immunotherapy, a me ka radiation therapy. ʻO ke koho ʻana o ka lāʻau lapaʻau e pili ana i nā ʻano kikoʻī o ka maʻi kanesa a me ke olakino holoʻokoʻa o ka mea maʻi. Hiki i nā poʻe maʻi me NSCLC ke komo i nā hoʻokolohua lapaʻau. E kamaʻilio me kāu kauka e aʻo hou e pili ana i nā hoʻokolohua lapaʻau a inā kūpono ia iā ʻoe. Shandong Baofa Cancer Research Institute's ʻO ka hoʻokō ʻana i ka noiʻi ʻo ia ka mea e noho mākou ma ka ʻoki o nā koho lapaʻau hou, i kekahi manawa ma o nā hoʻokolohua lapaʻau. ʻO ka hana ʻana i nā Hoʻoholo Lapaʻau ʻO ke koho ʻana i ka lapaʻau kūpono no NSCLC he hoʻoholo paʻakikī e hana ʻia me ke kūkākūkā me kāu hui mālama ola. ʻO nā kumu e noʻonoʻo ai, ʻo ia ka pae a me ka subtype o ka maʻi kanesa, ke olakino holoʻokoʻa o ka mea maʻi, a me kā lākou makemake. Mai hoʻokaʻulua e nīnau i nā nīnau a e ʻimi i ka manaʻo ʻelua inā pono.Prognosis a me Survival Rates ʻokoʻa nā helu ola no NSCLC ma muli o ke ʻano o ka maʻi kanesa, ka mālama ʻana i loaʻa, a me nā kumu ʻē aʻe. Hiki i ka ʻike mua ʻana a me ka mālama ʻana ke hoʻomaikaʻi i ka manawa o ke ola. Mākaʻikaʻi 5-Makahiki Ke Ola Ola Pae I 68-92% Pae II 53-60% Pae III 13-36% Papa IV Ma lalo o 10% *Kumu: American Cancer Society (www.cancer.org) He mea paʻakikī ka noho ʻana me NSCLC, akā he nui nā kumuwaiwai e kōkua ai i nā maʻi a me ko lākou ʻohana. Aia kēia mau kumuwaiwai i nā hui kākoʻo, nā lawelawe aʻoaʻo, a me nā papahana kōkua kālā.